Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $51.05 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Bioxytran Inc had its IPO on under the ticker symbol BIXT.
The company operates in the Healthcare sector and Biotechnology industry. Bioxytran Inc has a staff strength of 2 employees.
Shares of Bioxytran Inc opened at $0.42 at the start of the last trading session i.e. 2023-03-23.
The stocks traded within a range of $0.4 - $0.42, and closed at $0.4.
This is a -3.25% slip from the previous day's closing price.
A total volume of 38,561 shares were traded at the close of the day’s session.
In the last one week, shares of Bioxytran Inc have slipped by -10.98%.
Bioxytran Inc's Key Ratios
Bioxytran Inc has a market cap of $51.05 million, indicating a price to book ratio of 0 and a price to sales ratio of 532.5585.
In the last 12-months Bioxytran Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Bioxytran Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bioxytran Inc’s operating margin was 0% while its return on assets stood at -235.47% with a return of equity of 0%.
In Q3, Bioxytran Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Bioxytran Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bioxytran Inc’s profitability.
Bioxytran Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -25.581. Its price to sales ratio in the trailing 12-months stood at 532.5585.
Bioxytran Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- $3.00 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Bioxytran Inc ended 2023 with $448539.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $448539.00 while shareholder equity stood at $-2009539.00.
Bioxytran Inc ended 2023 with $0 in deferred long-term liabilities, $3.00 million in other current liabilities, 123014.00 in common stock, $-10411929.00 in retained earnings and $0 in goodwill. Its cash balance stood at $374190.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Bioxytran Inc’s total current assets stands at $374190.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $361.00 and inventory worth $0.
In 2023, Bioxytran Inc's operating cash flow was $-7713.00 while its capital expenditure stood at $7713.
Comparatively, Bioxytran Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Bioxytran Inc stock is currently trading at $0.4 per share. It touched a 52-week high of $1.25 and a 52-week low of $1.25. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.45 and 200-day moving average was $0.51 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6769.4% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Bioxytran Inc
Similar Industry Stocks (Biotechnology)
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.